Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone. / Langer, Seppo W; Thougaard, Annemette V; Sehested, Maxwell; Jensen, Peter Buhl.
I: Cancer Chemotherapy and Pharmacology, Bind 57, Nr. 1, 01.2006, s. 125-8.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone
AU - Langer, Seppo W
AU - Thougaard, Annemette V
AU - Sehested, Maxwell
AU - Jensen, Peter Buhl
PY - 2006/1
Y1 - 2006/1
N2 - Dexrazoxane has been reported to be protective against anthracycline induced subcutaneous ulceration in mice. It is currently under clinical investigation as an acute antidote in accidental anthracycline extravasation, for which indication topical dimethylsulfoxide (DMSO) and intralesional hydrocortisone are used empirically. We studied the effect in 72 mice of monotherapy with and combined therapy of intraperitoneal dexrazoxane, topical DMSO, and intralesional hydrocortisone as acute antidotes against ulceration after subcutaneous daunorubicin. Dexrazoxane completely prevented wounds from occurring, while neither DMSO nor hydrocortisone had any preventive effect. The addition of topical DMSO actually reduced the efficacy of dexrazoxane. In conclusion, the present study does not support the concomitant use of topical DMSO + systemic dexrazoxane or intralesional hydrocortisone + systemic dexrazoxane. Monotherapy with systemic dexrazoxane seems preferable and is highly efficacious in preventing ulceration.
AB - Dexrazoxane has been reported to be protective against anthracycline induced subcutaneous ulceration in mice. It is currently under clinical investigation as an acute antidote in accidental anthracycline extravasation, for which indication topical dimethylsulfoxide (DMSO) and intralesional hydrocortisone are used empirically. We studied the effect in 72 mice of monotherapy with and combined therapy of intraperitoneal dexrazoxane, topical DMSO, and intralesional hydrocortisone as acute antidotes against ulceration after subcutaneous daunorubicin. Dexrazoxane completely prevented wounds from occurring, while neither DMSO nor hydrocortisone had any preventive effect. The addition of topical DMSO actually reduced the efficacy of dexrazoxane. In conclusion, the present study does not support the concomitant use of topical DMSO + systemic dexrazoxane or intralesional hydrocortisone + systemic dexrazoxane. Monotherapy with systemic dexrazoxane seems preferable and is highly efficacious in preventing ulceration.
KW - Administration, Topical
KW - Animals
KW - Antibiotics, Antineoplastic/adverse effects
KW - Daunorubicin/adverse effects
KW - Dimethyl Sulfoxide/administration & dosage
KW - Drug Therapy, Combination
KW - Extravasation of Diagnostic and Therapeutic Materials/drug therapy
KW - Female
KW - Hydrocortisone/administration & dosage
KW - Injections, Intralesional
KW - Injections, Intraperitoneal
KW - Mice
KW - Mice, Inbred Strains
KW - Razoxane/administration & dosage
U2 - 10.1007/s00280-005-0022-7
DO - 10.1007/s00280-005-0022-7
M3 - Journal article
C2 - 16001176
VL - 57
SP - 125
EP - 128
JO - Cancer Chemotherapy and Pharmacology, Supplement
JF - Cancer Chemotherapy and Pharmacology, Supplement
SN - 0943-9404
IS - 1
ER -
ID: 247892218